StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN)

Stock analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a note issued to investors on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 price target on shares of Trevena in a research report on Thursday, November 14th.

Trevena Trading Down 6.6 %

Shares of TRVN opened at $1.69 on Friday. The stock has a market cap of $1.46 million, a P/E ratio of -0.04 and a beta of 1.08. Trevena has a 1 year low of $1.13 and a 1 year high of $19.23. The stock’s 50-day moving average price is $1.76 and its two-hundred day moving average price is $3.86.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The company had revenue of $0.28 million for the quarter. As a group, equities analysts forecast that Trevena will post -23.04 EPS for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.